We are committed to ensuring patients and families remain at the heart of our work as we strive to advance potential one-time gene therapies for people living with neurodegenerative diseases. Here we will provide updates on our progress.
PROCEED trial evaluating PR001 for GD1 announced
At Prevail, our team strives to develop disease-modifying gene therapies for patients with neurodegenerative diseases. Learn about our PROCEED trial which will evaluate PR001 for Type 1 Gaucher disease (GD1).